Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and a⦠read more
Healthcare
Biotechnology
43 years
USD
Exclusive to Premium users
$5.82
Price-0.51%
-$0.03
$89.153m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$24.891m
-
1y CAGR-
3y CAGR-
5y CAGR-$41.750m
-
1y CAGR-
3y CAGR-
5y CAGR-$301,508.10
-
1y CAGR-
3y CAGR-
5y CAGR$42.428m
$52.335m
Assets$9.907m
Liabilities$2.917m
Debt5.6%
-0.1x
Debt to EBITDA-$5.289m
-
1y CAGR-
3y CAGR-
5y CAGR